Phase II Study of Low-Dose Interferon Alfa 2B (Schering Plough) Plus Thalidomide (Celgene) for Patients With Resected High-Risk Soft Tissue Sarcoma
OBJECTIVES:
- Determine the efficacy of interferon alfa and thalidomide, in terms of time to disease
progression, in patients with surgically resected high-risk soft tissue sarcoma or bone
sarcoma.
- Determine the incidence of metastatic disease and overall survival in patients treated
with this regimen.
- Determine the clinical and laboratory toxic effects and the tolerability of this
regimen in these patients.
OUTLINE: Patients receive interferon alfa subcutaneously three times a week on weeks 1-60
and oral thalidomide once daily on weeks 13-60 in the absence of disease progression or
unacceptable toxicity.
Patients are followed every 6 weeks for at least 2 years.
PROJECTED ACCRUAL: A total of 20-48 patients will be accrued for this study.
Interventional
Primary Purpose: Treatment
Robert N. Taub, MD, PhD
Study Chair
Herbert Irving Comprehensive Cancer Center
United States: Federal Government
CDR0000069028
NCT00026416
October 2001
Name | Location |
---|---|
Herbert Irving Comprehensive Cancer Center | New York, New York 10032 |